{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T19:24:24Z","timestamp":1780428264252,"version":"3.54.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["108-S4335"],"award-info":[{"award-number":["108-S4335"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02884-z","type":"journal-article","created":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T09:01:58Z","timestamp":1715677318000},"page":"2966-2977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Early Therapeutic Drug Monitoring Optimizes Teicoplanin Use in Febrile Neutropenic Patients with Hematological Malignancies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-0573-2238","authenticated-orcid":false,"given":"Yu-Wen","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-An","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Chin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsing-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin-Zi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Hua","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Hsuan","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Chi","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Wen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,14]]},"reference":[{"issue":"4","key":"2884_CR1","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkx473","volume":"73","author":"CJ Byrne","year":"2018","unstructured":"Byrne CJ, Parton T, McWhinney B, et al. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy. J Antimicrob Chemother. 2018;73(4):995\u20131003.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"2884_CR2","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56\u201393.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2884_CR3","first-page":"455","volume":"38","author":"Infectious Diseases Society of Taiwan","year":"2005","unstructured":"Infectious Diseases Society of Taiwan, Hematology Society of Taiwan, Medical Foundation in Memory Dr. Deh-Lin Cheng, Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education, CY Lee's Research Foundation for Pediatric Infectious Diseases and Vaccine. Guidelines for the use of antimicrobial agents in patients with febrile neutropenia in Taiwan. J Microbiol Immunol Infect. 2005;38(6):455\u20137.","journal-title":"J Microbiol Immunol Infect"},{"issue":"4","key":"2884_CR4","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1093\/jac\/dkab499","volume":"77","author":"Y Hanai","year":"2022","unstructured":"Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother. 2022;77(4):869\u201379.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"2884_CR5","doi-asserted-by":"publisher","first-page":"4069","DOI":"10.1128\/AAC.00341-09","volume":"53","author":"S Svetitsky","year":"2009","unstructured":"Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53(10):4069\u201379.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"2884_CR6","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1128\/AAC.35.3.451","volume":"35","author":"P Van der Auwera","year":"1991","unstructured":"Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother. 1991;35(3):451\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"2884_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1097\/FTD.0000000000000906","volume":"43","author":"KI Sako","year":"2021","unstructured":"Sako KI, Nakamaru Y, Ikawa K, et al. Population pharmacokinetics of teicoplanin and its dosing recommendations for neutropenic patients with augmented renal clearance for hematological malignancies. Ther Drug Monit. 2021;43(4):519\u201326.","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2884_CR8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000481725","volume":"63","author":"Y Sato","year":"2018","unstructured":"Sato Y, Hiramatsu K, Suzuki Y, et al. Optimal trough concentration of teicoplanin in febrile neutropenic patients with hematological malignancy. Chemotherapy. 2018;63(1):29\u201334.","journal-title":"Chemotherapy"},{"key":"2884_CR9","doi-asserted-by":"crossref","unstructured":"Byrne CJ, Roberts JA, McWhinney B, et al. Variability in trough total and unbound teicoplanin concentrations and achievement of therapeutic drug monitoring targets in adult patients with hematological malignancy. Antimicrob Agents Chemother. 2017;61(6):e02466-16.","DOI":"10.1128\/AAC.02466-16"},{"issue":"9","key":"2884_CR10","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jiac.2020.06.006","volume":"26","author":"F Pea","year":"2020","unstructured":"Pea F. Teicoplanin and therapeutic drug monitoring: an update for optimal use in different patient populations. J Infect Chemother. 2020;26(9):900\u20137.","journal-title":"J Infect Chemother"},{"issue":"5","key":"2884_CR11","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1111\/j.1742-7843.2012.00862.x","volume":"110","author":"JT Wang","year":"2012","unstructured":"Wang JT, Liao HI, Wu Lin FL, Chang SC. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections. Basic Clin Pharmacol Toxicol. 2012;110(5):416\u201320.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"2884_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jiac.2013.08.006","volume":"20","author":"T Ueda","year":"2014","unstructured":"Ueda T, Takesue Y, Nakajima K, et al. High-dose regimen to achieve novel target trough concentration in teicoplanin. J Infect Chemother. 2014;20(1):43\u20137.","journal-title":"J Infect Chemother"},{"issue":"4","key":"2884_CR13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.ijantimicag.2015.05.019","volume":"46","author":"CJ Byrne","year":"2015","unstructured":"Byrne CJ, Egan S, Fennell JP, et al. Teicoplanin use in adult patients with haematological malignancy: exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity. Int J Antimicrob Agents. 2015;46(4):406\u201312.","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"2884_CR14","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1007\/s10096-019-03652-6","volume":"38","author":"SH Kim","year":"2019","unstructured":"Kim SH, Kang CI, Huh K, et al. Evaluating the optimal dose of teicoplanin with therapeutic drug monitoring: not too high for adverse event, not too low for treatment efficacy. Eur J Clin Microbiol Infect Dis. 2019;38(11):2113\u201320.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"2884_CR15","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/jac\/dkx289","volume":"72","author":"V Ramos-Martin","year":"2017","unstructured":"Ramos-Martin V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother. 2017;72(12):3382\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2884_CR16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bcpt.13029","volume":"123","author":"S Hu","year":"2018","unstructured":"Hu S, Wang T, You H, et al. Therapeutic drug monitoring of teicoplanin in haematological malignancy patients with febrile neutropenia and optimizing dosage regimens. Basic Clin Pharmacol Toxicol. 2018;123(5):594\u2013601.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"2884_CR17","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jfma.2019.10.005","volume":"119","author":"GJ Chen","year":"2020","unstructured":"Chen GJ, Lin SW, Tsai IL, Kuo CH, Wang JT, Hsieh SM. Therapeutic drug monitoring of the teicoplanin trough level after the loading doses in patients receiving venoarterial extracorporeal membrane oxygenation. J Formos Med Assoc. 2020;119(6):1086\u201392.","journal-title":"J Formos Med Assoc"},{"key":"2884_CR18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.talanta.2013.07.043","volume":"116","author":"IL Tsai","year":"2013","unstructured":"Tsai IL, Sun HY, Chen GY, Lin SW, Kuo CH. Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry. Talanta. 2013;116:593\u2013603.","journal-title":"Talanta"},{"key":"2884_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/IDR.S146961","volume":"11","author":"L Zhou","year":"2018","unstructured":"Zhou L, Gao Y, Cao W, et al. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections. Infect Drug Resist. 2018;11:29\u201336.","journal-title":"Infect Drug Resist"},{"issue":"1","key":"2884_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jinf.2013.08.018","volume":"68","author":"PC Matthews","year":"2014","unstructured":"Matthews PC, Chue AL, Wyllie D, et al. Increased teicoplanin doses are associated with improved serum levels but not drug toxicity. J Infect. 2014;68(1):43\u20139.","journal-title":"J Infect"},{"issue":"6","key":"2884_CR21","doi-asserted-by":"publisher","first-page":"405","DOI":"10.2165\/00003088-200443060-00004","volume":"43","author":"F Pea","year":"2004","unstructured":"Pea F, Viale P, Candoni A, et al. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin Pharmacokinet. 2004;43(6):405\u201315.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2884_CR22","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1111\/jcpt.13193","volume":"45","author":"K Saito","year":"2020","unstructured":"Saito K, Kamio S, Ito K, Suzuki N, Abe K, Goto T. A simple scoring method to predict augmented renal clearance in haematologic malignancies. J Clin Pharm Ther. 2020;45(5):1120\u20136.","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"2884_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40262-012-0018-5","volume":"52","author":"JA Roberts","year":"2013","unstructured":"Roberts JA, Pea F, Lipman J. The clinical relevance of plasma protein binding changes. Clin Pharmacokinet. 2013;52(1):1\u20138.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"2884_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2165\/11539220-000000000-00000","volume":"50","author":"M Ulldemolins","year":"2011","unstructured":"Ulldemolins M, Roberts JA, Rello J, Paterson DL, Lipman J. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet. 2011;50(2):99\u2013110.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"2884_CR25","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1007\/s00134-003-1859-z","volume":"29","author":"A Barbot","year":"2003","unstructured":"Barbot A, Venisse N, Rayeh F, Bouquet S, Debaene B, Mimoz O. Pharmacokinetics and pharmacodynamics of sequential intravenous and subcutaneous teicoplanin in critically ill patients without vasopressors. Intensive Care Med. 2003;29(9):1528\u201334.","journal-title":"Intensive Care Med"},{"issue":"4","key":"2884_CR26","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ijantimicag.2012.05.025","volume":"40","author":"T Yamada","year":"2012","unstructured":"Yamada T, Nonaka T, Yano T, et al. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation. Int J Antimicrob Agents. 2012;40(4):344\u20138.","journal-title":"Int J Antimicrob Agents"},{"key":"2884_CR27","first-page":"71","volume":"4","author":"M Seki","year":"2012","unstructured":"Seki M, Yabuno K, Miyawaki K, Miwa Y, Tomono K. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features. Clin Pharmacol. 2012;4:71\u20135.","journal-title":"Clin Pharmacol"},{"issue":"8","key":"2884_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/1120009X.2021.1931758","volume":"33","author":"X Wei","year":"2021","unstructured":"Wei X, Zhao M, Xiao X. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant Staphylococcus aureus in neutropenic patients with cancer by Monte Carlo simulations. J Chemother. 2021;33(8):547\u201353.","journal-title":"J Chemother"},{"issue":"1","key":"2884_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/bcpt.13679","volume":"130","author":"T Hirai","year":"2022","unstructured":"Hirai T, Hosohata K, Ogawa Y, Iwamoto T. Clinical predictors of nephrotoxicity associated with teicoplanin: meta-analysis and meta-regression. Basic Clin Pharmacol Toxicol. 2022;130(1):110\u201321.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"2884_CR30","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1128\/AAC.30.5.733","volume":"30","author":"A Bernareggi","year":"1986","unstructured":"Bernareggi A, Cavenaghi L, Assandri A. Pharmacokinetics of  [14C]teicoplanin in male rats after single intravenous dose. Antimicrob Agents Chemother. 1986;30(5):733\u20138.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02884-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02884-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:29:59Z","timestamp":1719570599000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02884-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,14]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2884"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02884-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,14]]},"assertion":[{"value":"24 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors, Yu-Wen Wang, Hsin-An Hou, Chien-Chin Lin, Hsing-Yu Lin, Pin-Zi Chen, Ching-Hua Kuo, Huai-Hsuan Chiu, Chia-Chi Chuang, Yi-Jing Chen, Shu-Wen Lin confirm that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical approval was obtained from the NTUH Research Ethics Committee (registration no. 201807132RINA) in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}